P.A.W. Capital Corp Has $2.55 Million Stake in InMode Ltd. (NASDAQ:INMD)

P.A.W. Capital Corp raised its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 64.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,000 shares of the healthcare company's stock after purchasing an additional 55,000 shares during the quarter. InMode makes up 6.2% of P.A.W. Capital Corp's holdings, making the stock its 8th biggest position. P.A.W. Capital Corp owned about 0.17% of InMode worth $2,554,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of INMD. Trust Co. of Vermont increased its position in InMode by 32.8% during the 4th quarter. Trust Co. of Vermont now owns 2,168 shares of the healthcare company's stock worth $48,000 after purchasing an additional 536 shares in the last quarter. CWM LLC boosted its holdings in InMode by 38.3% during the fourth quarter. CWM LLC now owns 2,454 shares of the healthcare company's stock worth $55,000 after purchasing an additional 680 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in InMode by 9.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 7,645 shares of the healthcare company's stock worth $165,000 after acquiring an additional 691 shares during the period. Newbridge Financial Services Group Inc. lifted its holdings in InMode by 69.2% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 2,200 shares of the healthcare company's stock valued at $49,000 after purchasing an additional 900 shares during the last quarter. Finally, Hohimer Wealth Management LLC lifted its holdings in shares of InMode by 6.5% in the first quarter. Hohimer Wealth Management LLC now owns 14,923 shares of the healthcare company's stock worth $322,000 after buying an additional 906 shares in the last quarter. 68.04% of the stock is owned by institutional investors.

InMode Stock Performance

INMD traded down $0.29 during trading on Wednesday, hitting $15.43. The stock had a trading volume of 876,802 shares, compared to its average volume of 1,381,960. InMode Ltd. has a twelve month low of $15.39 and a twelve month high of $39.48. The firm has a market capitalization of $1.30 billion, a P/E ratio of 7.31 and a beta of 2.18. The company's 50-day moving average price is $16.97 and its 200 day moving average price is $18.55.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Thursday, August 1st. The healthcare company reported $0.34 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.04). The firm had revenue of $102.60 million during the quarter, compared to analyst estimates of $104.81 million. InMode had a net margin of 35.81% and a return on equity of 21.00%. The company's revenue for the quarter was down 24.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.65 EPS. As a group, equities analysts expect that InMode Ltd. will post 1.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INMD has been the subject of several research reports. Barclays cut their target price on InMode from $33.00 to $29.00 and set an "overweight" rating for the company in a research note on Monday, July 15th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Thursday, July 11th. Jefferies Financial Group cut shares of InMode from a "buy" rating to a "hold" rating and lowered their target price for the company from $21.00 to $19.00 in a research note on Tuesday, July 23rd. Finally, Canaccord Genuity Group dropped their price target on shares of InMode from $21.00 to $16.00 and set a "hold" rating on the stock in a research note on Friday, July 12th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, InMode presently has an average rating of "Hold" and a consensus price target of $22.40.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.